Literature DB >> 7540196

The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes.

R Tedeschi1, Y T Foong, H M Cheng, P dePaoli, T Lehtinen, T Elfborg, J Dillner.   

Abstract

The BamHI-Z-encoded Epstein-Barr virus (EBV) replication activator (ZEBRA) is a key mediator of the switch from latency to productive cycle in EBV virus. Antibodies against ZEBRA are a marker of EBV reactivation and are regularly found among patients with infectious mononucleosis (IM) or nasopharyngeal carcinoma (NPC), but are only rarely found among healthy EBV-seropositive donors. In order to define the serologically reactive epitopes in the ZEBRA protein, we synthesized a set of overlapping peptides and tested them for reactivity with serum samples from EBV-seronegative persons, patients with NPC, IM, chronic fatigue syndrome, lymphoma or from healthy donors. Three major EBV-specific epitopes were found. These epitopes were further defined and optimized using substitution or truncation analogues of the peptides. Reactivity with epitope number 22 was found in 63% of NPC patients' sera, with < 2% of healthy donors' sera being positive. Serological reactivity with epitope number 19 was associated with IM (57% positive, 5% healthy donors positive). Serum antibodies against epitope 1 were found among healthy donors, but were significantly elevated among patients with NPC, IM or lymphomas. In conclusion, different serologically reactive epitopes in the ZEBRA protein associate with different EBV-associated diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540196     DOI: 10.1099/0022-1317-76-6-1393

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta.

Authors:  J Lu; S Y Chen; H H Chua; Y S Liu; Y T Huang; Y Chang; J Y Chen; T S Sheen; C H Tsai
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

Authors:  E Drouet; C Chapuis-Cellier; S Bosshard; C Verniol; A Niveleau; J L Touraine; J L Garnier
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.

Authors:  Nina Orlova; Mark H Fogg; Angela Carville; Fred Wang
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

4.  Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.

Authors:  Kelly J Yu; Wan-Lun Hsu; Ruth M Pfeiffer; Chun-Ju Chiang; Cheng-Ping Wang; Pei-Jen Lou; Yu-Juen Cheng; Patti Gravitt; Scott R Diehl; Alisa M Goldstein; Chien-Jen Chen; Allan Hildesheim
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

5.  Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients.

Authors:  R Tedeschi; J Dillner; P De Paoli
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

6.  Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.

Authors:  Rosamaria Tedeschi; Elisa Pin; Debora Martorelli; Ettore Bidoli; Alessia Marus; Chiara Pratesi; Maria Teresa Bortolin; Stefania Zanussi; Emanuela Vaccher; Riccardo Dolcetti; Paolo De Paoli
Journal:  Clin Vaccine Immunol       Date:  2007-02-28

7.  Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.

Authors:  Amolo S Asito; Erwan Piriou; Peter Sumba Odada; Nancy Fiore; Jaap M Middeldorp; Carole Long; Sheetij Dutta; David E Lanar; Walter G Jura; Collins Ouma; Juliana A Otieno; Ann M Moormann; Rosemary Rochford
Journal:  Infect Agent Cancer       Date:  2010-07-28       Impact factor: 2.965

8.  Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya.

Authors:  Erwan Piriou; Rhonda Kimmel; Kiprotich Chelimo; Jaap M Middeldorp; Peter Sumba Odada; Robert Ploutz-Snyder; Ann M Moormann; Rosemary Rochford
Journal:  J Med Virol       Date:  2009-06       Impact factor: 2.327

9.  Evaluation of an immunofiltration assay that detects immunoglobulin M antibodies against the ZEBRA protein for the diagnosis of Epstein-Barr virus infectious mononucleosis in immunocompetent patients.

Authors:  Dayana Bravo; Beatriz Muñoz-Cobo; Elisa Costa; M Angeles Clari; Nuria Tormo; David Navarro
Journal:  Clin Vaccine Immunol       Date:  2009-04-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.